Vojo Vukovic Purchases 60,000 Shares of Delcath Systems, Inc. (NASDAQ:DCTH) Stock

Delcath Systems, Inc. (NASDAQ:DCTH) insider Vojo Vukovic acquired 60,000 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were purchased at an average cost of $2.48 per share, for a total transaction of $148,800.00. Following the acquisition, the insider now owns 60,000 shares of the company’s stock, valued at approximately $148,800. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Delcath Systems Stock Performance

NASDAQ:DCTH traded up $0.25 during midday trading on Monday, reaching $2.70. The stock had a trading volume of 785,844 shares, compared to its average volume of 716,830. The company has a quick ratio of 1.53, a current ratio of 3.30 and a debt-to-equity ratio of 0.08. The stock has a market cap of $59.52 million, a P/E ratio of -0.81 and a beta of 0.51. The firm has a fifty day simple moving average of $3.62 and a two-hundred day simple moving average of $4.92. Delcath Systems, Inc. has a 12-month low of $2.25 and a 12-month high of $7.99.

Delcath Systems (NASDAQ:DCTH) last issued its earnings results on Monday, November 13th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.10). Delcath Systems had a negative net margin of 2,079.17% and a negative return on equity of 2,571.64%. The firm had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $0.68 million. On average, equities analysts expect that Delcath Systems, Inc. will post -2.59 EPS for the current year.

Hedge Funds Weigh In On Delcath Systems

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its holdings in shares of Delcath Systems by 107.8% in the 1st quarter. Tower Research Capital LLC TRC now owns 4,663 shares of the company’s stock valued at $26,000 after buying an additional 2,419 shares during the period. Geode Capital Management LLC boosted its position in shares of Delcath Systems by 4.8% during the 1st quarter. Geode Capital Management LLC now owns 62,733 shares of the company’s stock worth $361,000 after purchasing an additional 2,851 shares in the last quarter. BlackRock Inc. grew its stake in shares of Delcath Systems by 22.3% during the 1st quarter. BlackRock Inc. now owns 16,632 shares of the company’s stock worth $96,000 after purchasing an additional 3,032 shares during the period. Cibc World Market Inc. increased its holdings in shares of Delcath Systems by 4.0% in the 1st quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock valued at $568,000 after purchasing an additional 3,432 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Delcath Systems by 77.7% in the 2nd quarter. Renaissance Technologies LLC now owns 21,500 shares of the company’s stock valued at $125,000 after purchasing an additional 9,400 shares in the last quarter. Institutional investors and hedge funds own 85.15% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on DCTH shares. BTIG Research raised their price target on Delcath Systems from $19.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, August 15th. Roth Mkm lifted their target price on shares of Delcath Systems from $10.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, August 16th. HC Wainwright increased their price target on shares of Delcath Systems from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, August 15th. StockNews.com assumed coverage on shares of Delcath Systems in a research note on Thursday, October 5th. They issued a “sell” rating on the stock. Finally, Canaccord Genuity Group upped their target price on shares of Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, September 7th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $18.00.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.